Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Cognition Therapeutics (CGTX – Research Report) yesterday and set a price target ...

Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...

AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

Viking Therapeutics (VKTX) is up more than +5% after the company’s experimental pill, VK2735, showed weight loss in patients at higher doses with limited side effects. Air Transport Services Group ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...